Optimizing antibiotic treatment for patients with hospital-acquired pneumonia
Official title: Development and Evaluation of CRRT-Specific Precision Dosing Models to Optimize Beta-Lactam Treatment for Patients with Hospital-Acquired Pneumonia
Funded at Midwestern University · NIH-10874728 · Data updated 2026-11-12
This study is looking to make antibiotic treatments better for critically ill patients with hospital-acquired pneumonia caused by tough-to-treat bacteria, by personalizing the doses of medicine they receive to fit their unique needs.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Midwestern University NIH-funded |
| Lab location | 1 site (Downers Grove, United States) |
| Project start | June 23, 2023 |
| Project end | May 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $151,881 |
| NIH project number | 5R21AI174159-02 |
| Project ID | NIH-10874728 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are critically ill patients with hospital-acquired pneumonia who are receiving continuous renal replacement therapy.
✕Less likely to help
Patients who do not have hospital-acquired pneumonia or those not requiring continuous renal replacement therapy may not benefit from this research.
What this research studies
This research focuses on improving the treatment of hospital-acquired pneumonia (HAP) caused by antibiotic-resistant bacteria, particularly in critically ill patients undergoing continuous renal replacement therapy (CRRT). The study aims to develop precision dosing models that tailor antibiotic treatment to individual patient needs, addressing the challenges posed by changes in drug metabolism due to critical illness. By leveraging advanced pharmacokinetic and pharmacodynamic principles, the research seeks to enhance the effectiveness of beta-lactam antibiotics like meropenem, which are essential for treating HAP. The goal is to reduce treatment failures and mortality rates in this vulnerable patient population.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment outcomes and survival rates for patients suffering from hospital-acquired pneumonia.
How similar studies have gone: Previous research has shown promise in developing precision dosing strategies for other critical care conditions, indicating potential success for this novel approach.
Where this research is happening
-
Midwestern University
Downers Grove, United States Active
Researchers
- Principal investigator: Rhodes, Nathaniel James — Midwestern University
- Study coordinator: Rhodes, Nathaniel James
Related research
Other NIH-funded projects on the same topics.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Endothelial inflammation memory after sepsis and pneumonia
A scientist is studying how blood vessel cells “remember” sepsis and why survivors get worse when they catch pneumonia, with the goal of finding better ways to reduce organ damage.
-
Bacterial Biofilm Therapy with a Human Antibody to Help Antibiotics Work Better
A human antibody drug is being studied to disrupt bacterial biofilms and help standard antibiotics clear infections, especially around implants and catheters, in adults.
-
A tissue slice model to test treatments for Pneumocystis pneumonia in people with HIV/AIDS
Researchers are creating a lung-slice model to study Pneumocystis jirovecii pneumonia and test potential treatments using tissue from infected, immunosuppressed mice to better predict what might help people with HIV/AIDS.
-
Measuring respiratory and gut bacteria to predict pneumonia treatment failure
A project to understand how bacterial load in the lungs and gut changes during and after antibiotics for hospital-acquired and ventilator-associated pneumonia, with the goal of predicting which patients might fail treatment.
-
Better tests and treatments for Pneumocystis (PCP) pneumonia
Developing more accurate tests and safer treatment options for people with weakened immune systems who get Pneumocystis pneumonia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.